Christopher Wolfe
SelectQuoteAbout Christopher Wolfe
Christopher Wolfe (age 46) is an independent Class I director of SelectQuote, appointed on February 28, 2025 under Bain Capital Insurance’s director designation rights; he serves on the Healthcare Oversight Committee and brings deep insurance and healthcare investing and CFO experience to the board . He is a Managing Director at Bain Capital Insurance (since 2024), previously CFO of DFB Healthcare Acquisitions Corp. (2018–2023) and Partner at Capital Z Partners (2003–2017); he holds an AB, magna cum laude, from Harvard College . The Board has determined Wolfe is independent under NYSE standards, and all directors, including Wolfe, attended at least 75% of Board/committee meetings in FY2025 .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| DFB Healthcare Acquisitions Corp. (SPAC) | Chief Financial Officer | Jan 2018 – Jun 2023 | Led finance for publicly traded SPAC; capital markets and M&A execution |
| Capital Z Partners | Partner | 2003 – 2017 | Private equity investing in financial services; board oversight at portfolio companies |
| Permanent General Corp. | Director (prior) | Not disclosed | Governance oversight at direct-to-consumer insurer |
| Universal American Financial Corp. | Director (prior) | Not disclosed | Governance oversight at Medicare Advantage-focused insurer |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Bain Capital Insurance | Managing Director | 2024 – Present | Insurance investing and portfolio governance |
| Enhance Health (private) | Director | Feb 2024 – Present | Board member of health insurance distributor |
Board Governance
- Independence: Board determined Wolfe is independent under NYSE rules; majority-independent Board; independent Chair (Hawks) presides over executive sessions .
- Committee assignments (FY2025): Healthcare Oversight Committee member; not a chair. The committee is co-chaired by Dr. Patel and Mr. Devanny and expanded in 2025 to include healthcare compliance program oversight .
- Attendance: Each director attended at least 75% of Board and applicable committee meetings in FY2025 (Board met 4x; HOC met 4x) .
- Designation and potential influence: Wolfe was appointed under the Bain Director Designation Agreement tied to Bain’s February 2025 preferred equity financing; for so long as Bain retains specified ownership, it can nominate a director . The preferred stock arrangements also provide consent rights to Bain and Morgan Stanley on significant actions (e.g., indebtedness, related-party transactions, change of control until Feb 28, 2031), which can concentrate influence at investor-designees (oversight mitigated by Audit Committee review policies) .
| Committee | Role | FY2025 Meetings | Notes |
|---|---|---|---|
| Healthcare Oversight Committee | Member | 4 | Oversight of healthcare compliance and advisory board |
Fixed Compensation
| Component | Policy Amount | Wolfe FY2025 Earned (prorated from Feb 28, 2025) |
|---|---|---|
| Board annual cash retainer | $50,000 | $18,639 |
| Healthcare Oversight Committee member retainer | $5,000 | $1,694 |
| Committee chair retainers | Varies by committee | $0 (not a chair) |
| Meeting fees | None | $0 |
- Total FY2025 cash compensation: $20,333 .
Performance Compensation
| Grant Date | Award Type | Shares/Units | Grant-Date Fair Value | Vesting/Performance |
|---|---|---|---|---|
| Feb 28, 2025 | Initial RSU (director) | 28,508 | $129,997 | Vests in 3 equal annual installments on each of first 3 anniversaries, continued service required |
| Nov 12, 2024 (annual RSU to continuing directors) | RSU | Not applicable to Wolfe (joined 2025) | — | Program provides annual RSU retainer of ~$130,000; FY2025 awards anticipated at 2025 Annual Meeting for eligible directors |
Performance metrics applied to director pay: None disclosed for directors (equity is time-based RSUs; no PSUs/options for directors) .
Other Directorships & Interlocks
| Company | Relation to SLQT | Potential Interlock/Conflict Consideration |
|---|---|---|
| Bain Capital Insurance (employer) | SLQT sold senior non-convertible preferred to a Bain affiliate in Feb 2025; Bain has director nomination and certain consent rights | Wolfe is Bain’s designee; Board deems him independent; related-party and conflict approvals governed by Audit Committee policy |
| Enhance Health (director) | Private health insurance distributor | Industry overlap with SLQT’s distribution activities; no disclosed related-party transactions; recusal advisable if counterparties overlap |
Expertise & Qualifications
- Insurance and healthcare services investing/operator experience; prior director roles at insurance companies; SPAC CFO capital markets competency; Harvard AB, magna cum laude .
- Board-level healthcare oversight exposure via SLQT’s Healthcare Oversight Committee .
Equity Ownership
| Holder | Beneficial Ownership (Common) | % Outstanding | Derivative/Unvested |
|---|---|---|---|
| Christopher Wolfe | — | * (<1%) | 28,508 unvested RSUs outstanding as of 6/30/25; no options outstanding |
- Pledging/hedging: Company policy prohibits hedging, shorting, and pledging of SLQT stock by directors, with narrow exceptions subject to pre-approval .
- Ownership guidelines: Non-employee directors expected to hold stock equal to 5x annual cash retainer; Board determined all directors had attained the requisite level as of the record date (retention of 100% of vested shares until compliant) .
Governance Assessment
- Strengths: Independent determination; active committee service in healthcare compliance oversight; ≥75% attendance; balanced cash/equity director pay with no per-meeting fees; robust anti-hedging/anti-pledging and director ownership guidelines; strong 2025 say-on-pay outcome (For: 79,848,312; Against: 3,006,318; Abstain: 151,996; Broker non-votes: 31,437,302) indicating investor support for compensation programs overseen by the Board .
- Watch items / potential red flags: Investor-designee status under Bain’s Director Designation Agreement and broad consent rights tied to the 2025 preferred stock financing could create perceived conflicts or concentrated influence; mitigation relies on independent committee review and adherence to related-party policies .
- No disclosed related-party transactions involving Wolfe personally; no Section 16(a) delinquencies reported for Wolfe; no pledging/hedging noted .
Implication for investors: Wolfe augments SLQT’s board with sector-savvy capital allocation and insurance distribution expertise; while formally independent, his Bain designation and the Purchasers’ consent rights warrant monitoring for conflict management and governance checks during strategic transactions .